DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Leber Congenital Amaurosis - Pipeline Review, H1 2017" report to their offering.
Leber congenital amaurosis is an eye disorder that primarily affects the retina, which is the specialized tissue at the back of the eye that detects light and color. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
Pharmaceutical and Healthcare latest pipeline guide Leber Congenital Amaurosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Leber Congenital Amaurosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Leber Congenital Amaurosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Leber Congenital Amaurosis (LCA) - Overview
- Leber Congenital Amaurosis (LCA) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Leber Congenital Amaurosis (LCA) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leber Congenital Amaurosis (LCA) - Companies Involved in Therapeutics Development
- AmpliPhi Biosciences Corp
- Editas Medicine Inc
- Novelion Therapeutics Inc
- ProQR Therapeutics NV
- Spark Therapeutics Inc
For more information about this report visit http://www.researchandmarkets.com/research/x5jfhk/leber_congenital
